September 30, 2022
Article
As new mutational targets arise and genetic testing becomes more precise, the field of biliary tract cancer care may soon expand to accommodate a range of tailored treatments.
September 28, 2022
Article
Chemoimmunotherapy combinations, along with therapies targeting IDH1, FGFR2, and HER2 mutations, are ushering in a new era of treatment for biliary tract cancers.
September 26, 2022
Article
Flavio G. Rocha, MD, FACS, FSSO, discusses the types of biliary tract cancer and what has been learned about them, explains the effects of systemic therapy on surgery, and relays remaining questions pertaining to the efficacy of immunotherapy.
September 15, 2022
Article
Mark Yarchoan, MD, lays out the evolution of drug development in biliary tract cancer, discusses the findings from the TOPAZ-1 trial, and shares the positive future direction of immunotherapy in this disease.
September 08, 2022
Video
Mark Yarchoan, MD, discusses the addition of durvalumab (Imfinzi) to gemcitabine and cisplatin in biliary tract cancer.